Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Dermatology
•
Hidradenitis Suppurativa
•
Primary Care
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
Pt has not responded to Humira or Cosentyx. Pt is declining to have any infusion options.
Related Questions
What is your approach to diagnosing and managing methotrexate-induced alopecia?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
How do you manage oral ulcers as a side effect from leflunomide?
What are your vaccine recommendations while patients are on biologics?
What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?
Would you use febuxostat for an African-American patient with gout and previous cardiovascular events (stroke, MI) who tested positive for HLA-B*5801?